Psychopharmacology (1993) 110: 32{}-326

Psychopharmacology
I

.

©Springer-Verlag 1993

I

Effects of daily SKF 38393, quinpirole,
and SCH 23390 treatments on locomotor activity
and subsequent sensitivity to apomorphine*
Bruce A. Mattingly, James K. Rowlett, and Greg Lovell
Department of Psychology, 601 Ginger Hall, Morehead State University, Morehead, KY 40351, USA

Received June 8, 1992 / Final version July 28, 1992

Abstract. In three experiments, male Wistar rats

(250--350 g) were injected (SC) daily with the D 1-type
dopamine receptor agonist, SKF 38393 (0.0, 4.0, 8.0, or
16.0 mg/kg), the Dz-type dopamine receptor agonist,
quinpirole (0.0, 0.3, or 3.0 mg/kg), and/or the D 1 -type
dopamine receptor antagonist, SCH 23390 (0.0 or 0.5
mg/kg) for 8--10 days. After each daily injection, the rats
were tested for locomotor activity in photocell arenas for
20 min. Following this subchronic pretreatment, all rats
were challenged with the mixed dopamine receptor agonist apomorphine (1.0 mg/kg, SC) and tested for locomotor activity. SKF 38393 treatments produced a dosedependent decrease in locomotor activity which did not
significantly change across days. Quinpirole also depressed locomotor activity when first°injected, but this
quinpirole-induced inhibition of activity progressively
decreased across days. When subsequently. challenged
with apomorphine, rats in both the SKF 38393 and the
quinpirole pretreatment groups displayed greater loco, motor activity than rats pretreated with only vehicle.
Although SCH 23390 pretreatments did not affect subsequent sensitivity to apomorphine, SCH 23390 completely
blocked the effect of quinpirole. These results suggest
that although repeated D 1 receptor stimulation may be
sufficient to induce behavioral sensitization to apomorphine, Dz receptor stimulation also contributes to the
effect.
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The repeated administration of drugs that stimulate
dopamine receptors often results in the development of
behavioral sensitization (see Robinson and Becker 1986;
Kaliyas and Weber 1988). This behavioral sensitization
"' Portions of this paper were presented at the 1991 Society for
Neuroscience meetings, New Orleans, La. USA.
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effect has been demonstrated in rats !with both direct
(e.g., apomorphine) and indirect (amphetamine, cocaine)
dopamine agonists and is characterize<) by a progressive
augmentation of various drug-induced motor behaviors
(e.g., Kalivas and Weber 1986; Robipson and Becker
1986; Mattingly et al. 1988). Although recent evidence
clearly indicates that stimulation of dopamine receptors
is neccessary for the development of behavioral sensitization (e.g., Kuczenski and Leith 1981; Mattingly and
Rowlett 1989; Peris and Zahniser 1989), the specific
drug-induced neurobiological changes mediating the development of behavioral sensitization are unknown.
Dopamine agonists which induce 'the development
of behavioral sensitization (e.g., apomorphine, amphetamine, and cocaine) result in an ihcreased stimulation of both D.-type and Dz-type dopamine receptors.
In a recent study of apomorphine-induced sensitization,
we found that concurrent treatments' of rats with the
D 1 -type dopamine antagonist, SCH 23390, blocked both
the acute locomotor-activating effects of apomorphine
and the development of behavioral sensitization. In contrast, the Dz-type dopamine receptor antagonist, sulpiride, blocked the acute effects of apomorphine, but did
not prevent the development of behavioral sensitization
(Mattingly et al. 1991). Similarly, amphetamine-induced
behavioral sensitization may be blocked by D,, but not
D 2 -type, dopamine receptor antagonists (Stewart and
Vezina 1989; Vezina and Stewart 1989). These findings,
of course, suggest that repeated stimulation of the dopamine D 1-type receptor is both necessary and sufficient to
induce the development of behavioral sensitization. In
the present study, we tested this assumption by treating
rats daily with either the selective Ii,-type dopailline
agonist, SKF 38393 (expt I) or the Dz-type agonist,
quinpirole (expt 2), and testing for locomotor activity.
Following this subchronic pretreatm~nt, all rats were
then tested for locomotor activity afte~ a challenge injection of the mixed Di/Dz agonist, apomorphine. Based
upon our. prior work, we expected the rats pretreated
with SKF 38393, but not quinpirol~, to demonstrate
behavioral sensitization to apomorphihe.
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Subjects. Seventy-three male Wistar albino rats (Harlan Industries,
Indianapolis, IN) weighitlg between 250 and 350 g served as subjects. All rats were housed individually in hanging wire-mesh cages
in a colony room with a 12-h light-dark cycle and fqod and water
available continuously. All behavioral testing.was conducted during
the light phase of the cycle.
Apparatus. Activity measures were taken in two BRS/Lehigh Valley
cylindrical activity drums (Model 145-03). The floor of each drum
was made of 4 cm diamond-shaped wire mesh and was 60 cm in
diameter. The interior wall of each drum was painted flat black and
was 43 cm high. Each drum was located in a separate soundattenuated experimental cubicle that was kept dark during testing.
Two banks of three infrared photocells were mounted on the
outside of each drum. The six photocell beams were approximately
12 cm apart arranged in a criss-cross pattern 2.5 cm above the drum
floor. The photocell banks were connected to back-path eliminator
diodes. Movement of the rat through a photocell beam sent a single
pulse to the counters. Simultaneous pulses (i.e., pulses spaced less
than 0.05 s apart) such as might occur when two beams are broken
at their intersection were recorded as a single count by this method.
Thus, locomotor activity was operationalized as the cumulative
number of photocell interruptions per unit time.
Drugs. Apomorphine hydrochloride (Sigma) and SKF 38393 (Research Biochemicals) were diss_olved daily in 0.001 N HCL. Apomorphine was injected in a volume of 1.0 ml/kg and SKF 38393 was
injected in a volume of 1.5 ml/kg. Quinpirole hydrochloride (Research Biochemicals) was mixed in distilled H 2 0· and injected in a
volume of 1.0 ml/kg. All injections were SC. Control injections were
given using the appropriate vehicle using the same route and volume
as the correspon-ding drug injection.
Design and procedure. At the beginning of experiment I, 48 rats were
randomly assigned, in equal numbers, to one of four treatment
groups: 0 (vehicle), 4.0, 8.0, or 16.0 mg/kg SKF 38393. On each of
the first 10 days of the experiment (pretreatment phase), the rats
were injected with the appropriate dose of SKF 38393 and then
tested for locomotor activity 15 min after the injection. Locomotor
activity measurements were taken for 20 min each day. On day 11
of the experiment all rats. were given a challenge injection of apomorphine (1.0 mg/kg) and then tested for activity 15 min later.
Experiment 2 was the same as experiment 1 except three groups of
rats (N~8-9/group) were given either 0 (vehicle), 0.3, or 3.0 mg/kg
quinpirole during the pretreatment phase.

Data analysis. Significant differences among the groups in mean
activity counts across days were determined with mixed-factor
analyses of variance (ANOV A) using drug treatment group as a
between factor and daily test session as a repeated measure. When
appropriate, additional one-way ANOVAs or Neuman-Keuls post
hoc test were performed.
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Fig. 1. Mean activity counts per 20 min' session across the
10 pretreatment days for rats (N= 12/group)' injected with either
vehicle (0-0) or SKF 38393. SKF 38393: 4.0 mg/kg (•-•);
8.0 mg/kg (.l-.l); 16.0 mg/kg (•-•). The standard error of the
mean for the groups' activity on day 10 was 65.25

changed across the ten daily injection-test sessions. That
is, although the groups gradually decre'.ased activity with
repeated testing, the activity of the SKF 38393 groups,
particularly the 8.0 and 16.0 mg/kg groups, remained
significantly lower than that of the vehicle control rats.
The ANOVA performed on these data revealed a significant drug effect [F(3, 44)= 12.10, P<o:oool], day effect,
[F(9, 396)= 50.64, P< 0.0001], and Drug x Day interaction, [F(27,396)= 1.89, P<0.01]. This latter interaction
was largely due to the fact that the groups decreased
activity at slightly different rates over the first 3 test days.
Expt I: apomorphine challenge of SKF 38393 pretreated
rats. The mean activity counts of the four pretreatment
groups after a challenge injection of apomorphine
(1.0 mg/kg) on test day 11 are shown in Fig. 2. As shown
in this figure, rats previously given ten daily injections of
SKF 38393 displayed significantly greater levels of locomotor activity in response to the apomorphine challenge
injection than rats previously treated ~ith only vehicle.
As expected, the ANOVA performed :on these data revealed a significant drug effect, [F(3, 44) = 3.55, P< 0.05].
Subsequent analysis of this drug effect with NewmanKeuls post hoc tests indicated that all ·three SKF 38393
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Results
Expt I: chronic SKF 38393 and activity. The mean activity counts for the four groups injected daily with various
doses of SKF 38393 across the first ten test days are
shown in Fig. I. As may be seen in this figure, rats
injected with SKF 38393 were significantly less active
than the vehicle control rats on the first test day. Moreover, this drug-induced decrease in locomotor activity
was dose-dependent and was maintained relatively un-
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SKF 38393 (MG/KG) PRETREATMENT

Fig. 2. Mean activity counts ( + SEM) during the 20 min session
following a challenge injection of apoinorphine for rats
(N= 12/group) previously treated daily with e'ither vehicle or SKF
38393. (*P<0.05 vs 0 mg/kg group)
'
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pretreatment groups were significantly more active following apomorphine than the vehicle control group
(Ps<0.05).
Expt 2: chronic quinpirole and activity. The mean activity

counts for the three groups of rats injected daily with
either quinpirole or vehicle are displayed in Fig. 3. As
may be seen in this figure, quinpirole induced a significant depression in locomotor activity following the first
injection. This quinpirole-induced inhibition of locomotor activity, however, progressively decreased with
repeated injections. Indeed, by day 4 of testing the rats
injected with quinpirole did not differ significantly from
those injected with vehicle, and by the end of testing
quinpirole-treated rats were more active than vehicletreated rats. The ANOVA performed on these data
indicated that the main effect of drug was not significant.
As expected, however, both the main effect of
day and the Drug x Day interaction were significant
[F(9,198)= 13.95, P<0.0001, and F(18, 198)=9.49,
P< 0.0001, respectively]. To further analyse this interaction, a one-way ANOVA was performed on the rats'
activity scores on the last pretreatment test day (10). The
results of this analysis revealed no significant differences
in activity among the groups (P> 0.05). Thus, the quin(f)
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Fig. 3. Mean activity counts per 20 min session across the
10 pretreatment days for rats (N=8-9/group) injected with either
vehicle (o-o) or quinpirole. Quinpirole: 0.3 mg/kg (•-•);
3.0 mg/kg (.&.-.&). The standard error of the mean for the groups'
activity on day I 0 was 179
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Fig. 4. Mean activity counts per 20 min session ( + SEM) following
a challenge injection of apomorphine for the three groups of rats
(N = 8-9 each) previously treated daily with either vehicle or quinpirole. (*P<0.05 vs 0 mg/kg group)

pirole-treated rats were not significantly more,active than
the vehicle-treated rats on this test day."·
Expt 2: apomo1phine challenge of quinpirole pretreated
rats. The mean activity counts of the three quinpirole

pretreatment groups after a challenge injection of apomorphine on day 11 of testing are shown in Fig. 4. It is
evident from this figure that the rats pretreated for
10 days with 3.0 mg/kg quinpirole displayed significantly
greater locomotor activity in response to a challenge
injection of apomorphine than did either the vehiclecontrol group or the 0.3 mg/kg quinpirole pretreatment
group. As expected, the ANOVA performed on these
data revealed a significant drug effect [F(2,24)= 3.75,
P< 0.05].
Experiment 3

In experiment 2, rats pretreated with the D 2 receptor
agonist, quinpirole displayed significantly greater levels
of locomotor activity following an apomorphine injection than did rats pretreated with vehicle. This finding
was unexpected because our previous work had indicated
that rats repeatedly treated with the mixed D 1 /D 2 dopamine receptor agonist, apomorphine, along with the
selective D 1 dopamine antagonist SCH 23390 do not
become sensitized to apomorphine (Mattingly et al.
1991). This apparent discrepancy in the effects of repeated D 2 receptor stimulation may be related to the
presence or absence of D 1 "tone". That is, repeated D 2
receptor stimulation may have been effective in expt 2
because th.e D 1 receptors were not blocked as they were
in our previous study. If so, then the effects of repeated
quinpitole treatments, like apomorphine treatments,
should be blocked by concurrent treatments with the D 1
receptor antagonist, SCH 23390. In experiment 3,
therefore, groups of rats were injected daily with quinpirole and/or SCH 23390 for 8 days and then tested for
locomotor activity after a challenge injection of apomorphine.
Materials and methods
Subjects, apparatus, and drugs. The subjects were 32 male Wistar
albino rats (Harlan Industries, Indianapolis, IN) weighing between
250 and 300 g at the beginning of the experiment. The apparatus
was the same as in the preceding experiments. Likewise, quinpirole
and apomorphine were obtained, prepared, and administered as
described previously. SCH 23390 (Research Biochemicals, Inc.) was
dissolved daily in distilled H 2 0 and injected SC in a volume of
1.0 ml/kg.

Design and procedure. The rats were randomly assigned, in equal
numbers, to one of four groups comprising the two (SCH 23390
dose: 0 or 0.5 mg/kg)xtwo (quinpirole dose: 0 or 3.0 mg/kg)
factorial design. On day 1 of the pretreatment phase each rat was
first injected with either vehicle or SCH 23390 and returned to its
home cage. Fifteen minutes later each rat was injected with either
quinpirole or vehicle and again returned to its home cage. Fifteen
minutes after the second injection each rat was placed into the
activity drum and activity counts were recorded for 20 min. This
injection-test procedure was repeated daily for 8 days. On day 9, all

323
rats were given a challenge injection of apomorphine (1.0 mg/kg)
and tested for activity 15 min after the injection.

(/)
1z
1600

APOMORPHINE CHALLENGE

*

:0

0

Results
Expt 3: quinpiro/e, SCH 23390, and activity. The mean
activity counts of the four groups across the eight pretreatment sessions are presented in Fig. 5. As may be seen
in this figure, rats injected with SCH 23390 and/or quinpirole were significantly less active on day I than rats
injected with only vehicle. Further, the S_C~ 233?0-mduced inhibition of locomotor activity did not sigmficantly change across the 8 pretreatment days. In contrast, the quinpirole-induced inhibition of locomotor activity decreased significantly across the pretreatment
days for rats injected with vehicle, but not for those
injected with SCH 23390. That is, concurrent S_CH 233_90
treatments completely blocked the increase m act!V!ty
observed across days in quinpirole-injected rats. The
three-factor ANOVA performed on these data revealed
a significant main effect for SCH 23390 [F(l, 28) = 74.60,
p < 0.000 l ], and several significant interactions including
the SCH 23390 x Quinpirole x Day interaction [F(7, 196)
= 8.35, P < 0.0001]. To further analyse this latter interaction a separate ANOVA was performed on the last
pret~eatment day (day 8) al on~. Consistent _with the
above interpretation, this analysis revealed a sigmficant
main effect of SCH 23390 [F(l, 28)= 50.37, P<0.0001],
however neither the main effect of quinpirole nor the
SCH 23390 x Quinpirole interaction was significant
[Fs < 1.00]. Thus, at the end of the_ pretr~ahnent phase,
rats injected with SCH 23390 remamed sigmficantly less
active then the vehicle control rats, whereas rats treated
daily with only quinpirole did not significantly differ
from rats injected daily with only vehicle.
Expt 3: apomorphine challenge of SCH 23390/quinpirole
pretreated rats. The mean activity counts of the four
groups of rats after the challenge injection of apomorphine on day 9 of testing are presente<J m Fig. 6. Consistent with the results of experiment 2, rats pretreated for
8 days with only quinpirole displayed significantly

Fig. S. Mean activity counts per 20 min session across t?~ 8 pretre~t
ment days for the four groups of rats (N=8/grqup) 1~1ected d~dy
with either vehicle (V) or SCH 23390 (S) followed by either vehicle
or quinpirole (Q) (0-'-0) V-V; (•-•) V-Q; (D-D) S-V; (•-•)
S-Q. The stardard error of the mean for the groups' activity on day
8 was IOI
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Fig. 6. Mean activity counts per 20 min session ( + SEM) following
a challenge injection of apomorphine for groups of rats
(N 8/group) previously treated for 8 d~ys with eithe: v~hicle (V)
or SCH 23390 (S) followed by either vehicle (V) or qump1role (Q).
(*P<0.05 vs V-V group)
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greater locomotor activity following ~n injection of apomorphine than did rats pretreated with only vehicle. In
contrast, the activity of rats pretreated with only
SCH 23390 for 8 days did not differ significantly from the
vehicle-only group on this test day. Mdre important, rats
pretreated with both SCH 23390 and quinpirole for
8 days did not differ from the vehicle control group. In
other words concurrent .treatments of rats with
SCH 23390 blocked the effects of repeated quinpirole
treatments on apomorphine-induced activity. Consistent
with this interpretation, the ANOVA performed on these
data revealed a significant main effect of SCH 23390
[F(l, 28)=8.44, P<0.01] and a ·significant SCH
23390 x Quinpirole interaction [F(l, 28) = 8.01, P.< 0.01].
A Neuman-Keuls analysis of this significant interaction
indicated that the vehicle-quinpirole rats were significantly more active than the other thr~e groups, [Ps <
0.05]. None of the other group comparisons were significant.
It might be noted that in this experiment the rats
previously given only vehicle displayed ¥re~ter activity
following the apomorphine challenge mject10n than m
either of the preceding two experiments. Moreo_ver, m
contrast to the first two experiments, apomorphme did
not produce a decrease in activity in vehicle rats relative
to their activity level following vehicle, on the precedmg
day. This variability in the initial effects of apomorphme
is not unusual. Moreover, the lack of an apomorphmeinduced increase in activity following the first injection
of apomorphine is consistent with our previous work (see
Mattingly et al. 1988, 1991; Mattmgly and Gots1ck 1989;
Rowlett et al. 1991). It should be emphasized, however,
that the development of behavioral sensitization to apomorphine is a highly reliable and robust phenomenon,
and despite changing baselines, the relative effects of
various treatments on apomorphine-iqduced locomotor
activity have also been reliable across experiments (cf,
quinpirole groups in Figs. 4 and 6).
'
Discussion

I

It is evident from the present results that selective stimu-

lation of the D 1-type dopamine receptor with SKF 38393
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in rats significantly inhibited locomotor activity, Moreover, this inhibition was dose-dependent and did not
significantly change with repeated treatments. The D 2 type dopamine receptor agonist, quinpirole, also decreased locomotor activity when first administered, but
this inhibition rapidly decreased with repeated treatments. In fact, with repeated treatments quinpirole appeared to have a stimulating effect on locomotor activity
relative to the vehicle treated rats. Whether this increase
in activity with repeated quinpirole treatments should be
interpreted as tolerance or sensitization, however, is un-

clear, since the quinpirole treated rats were not significantly more active than the vehicle treated rats at the end
of training. Although the time course is quite different,
the direct D,-type dopamine receptor agonist bromocriptine also depresses locomotor activity when first
presented, bnt with repeated treatments results in an
increase in locomotor activity (Hoffman and Wise 1992).
The inhibition oflocomotor activity induced by quinpirole was expected and may be related to the stimulation
of D 2 -type autoreceptors. Dopamine autoreceptors appear to be part of a negative feedback loop which, when
stimulated, result in a decrease in the synthesis and release of dopamine as well as a decrease in the firing rate
of dopamine cells (see Wolf and Roth 1987; Drukarch
and Stoof 1990; Lynch 1991, for reviews). Dopamine
autoreceptors are generally considered to be of the D 2 type (but see Diana et al. 1991) and appear to be more
sensitive to various dopamine agonists compared to postsynaptic D 2 -type receptors (see Skirboll et al. 1979;
Drukarch and Stoof 1990). Thus, although high doses of
direct agonists such as apomorphine often increase locomotor activity, low doses typically result in an inhibition
of activity due to selective autoreceptor stimulation (e.g.,
Mattingly et al. 1988). The initial inhibition of activity
induced by quinpirole in the present study is consistent
with this view. Moreover, the rapid tolerance that developed to the inhibitory effects of quinpirole also suggests autoreceptor involvement. That is, a number of
electrophysiological studies have demonstrated that
autoreceptors rapidly become subsensitive to dopamine
agonists with repeated exposure (e.g., Rebec and Lee
1982). Hence, the progressive increase in activity observed in the present study with repeated quinpirole
treatments may be related to the development of autoreceptor subsensitivity.
As discussed above, low doses of the mixed Di/D 2
dopamine receptor agonist apomorphine usually
produce hypoactivity and this decrease in activity has
generally been attributed to selective D 2 autoreceptor
stimulation (e.g., Radhakishun and Van Ree 1987). The
present results, however, indicate that stimulation of
Di-type dopamine receptors with SKF 38393 can also
produce locomotor hypoactivity. This finding suggests
that the inhibitory effects of low doses of some dopamine
agonists might be due to Di postsynaptic receptor stimulation rather than to simply D 2 autoreceptor activation.
Consistent with this view, other recent work suggests that
the behavioral effects of low dose apomorphine treatments cannot be explained exclusively by selective autoreceptor activation (see Stahle and Ungerstedt 1989,

1990; Lynch 1991). Alternatively, it is possible that SKF
38393 reduced activity in the present study because the
doses used stimulated both postsynaptic Di receptors
and D 2 autoreceptors. If this were the case, however, the
SKF 38393-induced inhibition of activity should have
progressively diminished over days in a manner similar
to quinpirole. As noted previously, the SKF 38393-induced decrease in locomotor activity did not significantly
change with repeated treatments. Likewise, SKF 38393induced grooming behavior in rats does not significantly
increase with daily treatments (White et al. 1990; Niesewander et al. 1991 ). Thus, the possibility exists that the
hypoactivity observed after mixed agonist treatments is
mediated in part by Di receptors (cf, Vezina et al. 1991).
Although SKF 38393 treatments decreased locomotor
activity across the IO pretreatment days, SKF 38393-pretreated rats displayed significantly greater levels of activity in response to an apomorphine-challenge injection
than rats pretreated with only vehicle. This finding is
consistent with our previous work in which rats were
treated daily with the mixed dopamine agonist apomorphine along with the D 2 receptor antagonist sulpiride
(Mattingly et al. 1991). Although this combination of
drugs resulted in an acute decrease in locomotor activity
across days, rats treated in this manner displayed a sensitized locomotor response to a subsequent challenge
injection of apomorphine. Together these results suggest
that repeated stimulation of the dopamine Di-type receptor alone is sufficient to induce the development of
behavioral sensitization to the mixed dopamine agonist
apomorphine. Based upon both behavioral aud electrophysiological data, other researchers have also concluded that repeated dopamine Di receptor stimulation
may be the crucial factor neccessary for the induction of
agonist-induced behavioral sensitization (e.g., Braun and
Chase 1988; Criswell et al. 1989; Henry et al. 1989;
Stewart and Vezina 1989; Vezina and Stewart 1989;
White et al. 1990; Henry and White 1991). It should be
noted, however, that SKF 38393 is not a full but rather
a partial Di dopamine receptor agonist. Consequently,
it might be argued that the increase in sensitivity to
apomorphine observed in the present study following
repeated SKF 38393 treatments could be due to an upregulation of Di dopamine receptors. There are at least
two arguments against this alternative interpretation.
First, although an increase in dopamine Di receptors in
the substantia nigra has been ·reported following chronic
methamphetamine treatments (Ujike et al. 1991 ), chronic
administration of SKF 38393 alone does not alter either
the number or affinity of Di receptors (Rowlett, Mattingly, and Bardo, submitted for publication; Neisewander et al. 1991). Second, if the increase in sensitivity to
apomorphine was due to the partial agonist effects of
SKF 38393, then repeated SCH 23390 treatments should
produce a similar increase in sensitivity to apomorphine.

Repeated treatment with the dopamine Di receptor antagonist SCH 23390, however, does not result in an
increased activity response to a subsequent challenge
injection of apomorphine (see expt 3; Mattingly et al.
1991 ).
As discussed previously, we have found that the de-
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velopment of behavioral sensitization to the mixed D 1 /
Dz dopamine agonist apomorphine could be completely
blocked by the concurrent administration of the dopamine D 1 receptor antagonist SCH 23390 (Mattingly et al.
1991). This finding suggests that repeated stimulation of
the Dz receptor alone is not sufficient to induce behavioral sensitization. In the present study, however, rats
previously given daily quinpirole (3.0 mg/kg) treatments
displayed a greater activity response to apomorphine
than rats pretreated with only vehicle. Consistent with
this result, it has recently been reported that rats are also
more sensitive to the locomotor-activating effects of cocaine after subchronic quinpirole pretreatments (Horger
and Schenk 1991). These results, of course, clearly suggest the involvement of Dz receptors in the development
of behavioral sensitization. One possible explanation of
these findings is that repeated quinpirole treatments induce autoreceptor subsensitivity. Thus, when subsequently challenged with a mixed dopamine agonist such
as apomorphine or cocaine, there is a greater net increase

in postsynaptic dopamine receptor stimulation, which in
turn, leads to greater locomotor activity. Interestingly,
autoreceptor tolerance or subsensitivity was one of the
earliest explanations for the development of behavioral
sensitization (Muller and Seeman 1979; Robinson and
Becker 1986), and a number of behavioral, electrophysiological, and neurochemical effects of repeated agonist
treatments are consistent with this view (Rebec and Lee
1982; Henry and White 1991; Rowlett et al. 1991). But
while an autoreceptor subsensitivity argument appears
plausible, this explanation cannot account for the fact
that the 0.3 mg/kg dose of quinpirole used in the present
study did not increase subsequent sensitivity to apomorphine. Like the 3.0 mg/kg dose, this low dose of quinpirole resulted in a significant inhibition in activity that
diminished across the 10 pretreatment days (see Fig. 3).
This finding suggests that the 0.3 mg/kg dose of quinpirole also induced autoreceptor subsensitivity. Yet, this
dose of quinpirole did not increase subsequent sensitivity
to apomorphine. Thus, although autoreceptor subsensitivity may be a contributing factor to the development
of sensitization, this latter finding suggests that some
minimal level of postsynaptic Dz receptor stimulation is
also necessary to produce this effect. Consistent with this
view, other evidence suggests that autoreceptor tolerance
cannot account exclusively for the development of behavioral sensitization to mixed dopamine agonists (see
Robinson and Becker 1986; Mattingly et al. 1991; Rowlett et al. 1991). Dopamine Dz antagonists, for example,
do not block the development of sensitization to either
apomorphine or amphetamine (Stewart and Vezina
1989; Vezina and Stewart 1989; Mattingly et al. 1991).
Interestingly, in experiment 3, the effect of repeated
Dz receptor stimulation with quinpirole on subsequent
sensitivity to apomorphine was completely blocked by
the D 1 receptor antagonist, SCH 23390. This finding is
consistent with previous work indicating that the development of behavioral sensitization to mixed Di/Dz
dopamine agonists, such as apomorphine and amphetamine, may also be prevented by the blockade ofD 1
dopamine receptors (Stewart and Vezina 1989; Vezina

I

and Stewart 1989; Mattingly et al. 1991). Taken together,
these results suggest that repeated dopamine Dz receptor
stimulation is neither necessary nor S:Ufficient for the
induction of behavioral sensitization. However, in the
presence of D 1 receptor "tone", as in experiment 2, re-

peated Dz stimulation may contribute to the magnitude
of the sensitization effect. Whereas, in the absence ofD 1
"tone", repeated D 2 receptor stim-qlation will not
produce behavioral sensitization (expt 3; Stewart and
Vezina 1989; Mattingly et al. 1991). These results are
consistent with the idea of an "enabliµg" function for
dopamine D 1 -type receptors (see Clark and White 1987,
for review).
Although the above interpretation accounts for the
present results as well as our previous findings using
selective antagonists with repeated apomorphine treatments (Mattingly et al. 1991), at least one alternative
explanation should be noted. It could be argued, for
example, that the ability of SCH 23390 to block the
effects of repeated quinpirole or apomorphine treatments
on subsequent sensitivity to apomorphine is due to a
general depression of locomotor activity rather than to
a specific blockade of dopamine D 1 re~eptors (cf Hirabayasi et al. 1991). Although this explanation cannot be
exclusively ruled out on the basis of thb present results,
there are several arguments against this ~iew. First, many
treatments which significantly reduce lotomotor activity
do not block the development of behavioral sensitization. For example, the dopamine Dz anfugonist sulpiride
depresses activity and blocks the acute locomotor activating effects of apomorphine, but does not prevent the
development of behavioral sensitization to apomorphine
(Mattingly et al. 1991). Likewise, low doses of apomorphine inhibit locomotor activity but siill result in the
development of behavioral sensitization '(Mattingly et al.
1988). Further, rats repeatedly treated with apomorphine
in their home cage without any opportunity to explore
the test environment display sensitization when subsequently challenged with apomorphine in the testing environment (Mattingly and Gotsick 1990). Also it may be
noted that SKF 38393 treatments decreased activity in a
dose-dependent manner in experiment l, but resulted in
a greater activity response to a subsequent challenge dose
ofapomorphine. Finally, we have recently found that the
same dose of SCH 23390 used in the present study does
not block the development of behavioral sensitization to
cocaine (Mattingly et al. 1992). Thus, 'treatments that
depress locomotor activity in the test chambers do not
always prevent the development of behavioral sensitization.

In conclusion, the present results indicate that re-·
peated stimulation of either the D 1 -type or D,-type
dopamine receptor can lead to greater activity in response to the mixed dopamine agonist, apomorphine.
These findings are consistent with the view that repeated
D 1 receptor stimulation is both necessary and sufficient
apomorphine.
to induce behavioral sensitization
Along with previous findings, the preserit results suggest
that while Dz receptor stimulation may not be necessary
for the development of behavioral sensitization to apomorphine, it does contribute to the magnitude of the
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effect. These findings lend additional support to the view
that multiple pre- and postsynaptic mechanisms may be
involved ill the development of behavioral sensitization
to dopamine agonists (cf Henry and White 1991).
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